Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII)
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed
to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well
characterized PCOS.